Clinical trials
Diabetic Nephropathies clinical trials
Below are recruiting diabetic nephropathies clinical trials, each written for real people, not researchers. We’re tracking 30 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06466135RecruitingPhase 2
Study of WAL0921 for glomerular kidney diseases
This study tests a new drug called WAL0921 for people with certain types of kidney disease. The goal is to see if it can help protect kidney function.
Los Angeles, CaliforniaAges 18–75 - NCT07187713RecruitingPhase 4
Study of ACE Reno, Pico Cell Matrix for kidney health
This trial tests a new treatment called ACE Reno, Pico Cell Matrix to see if it can improve kidney function in people with chronic kidney disease (CKD) at various stages. It may be an option if you have early to moderate kidney issues (including after a transplant) and are already on standard therapies.
Giza, GZAges 18–80 - NCT02818192Recruiting
Kid-focused study to track kidney issues in type 2 diabetes
This study follows young people with type 2 diabetes to better understand risks for kidney problems over time. It may help researchers find earlier warning signs and improve care for adolescents living with type 2 diabetes.
Winnipeg, ManitobaAges 10–18 - NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT06954090Enrolling by invitationPhase 4
Urine test to guide early treatment in type 2 diabetes
This study looks at whether a urine test can help doctors choose the right medicines earlier to prevent kidney and heart problems in people with type 2 diabetes. You may join if you have type 2 diabetes but no severe heart failure.
Herlev, Hajdú-BiharAges 18 years+ - NCT00977977RecruitingPhase 2
Rituximab plus cyclosporine for membranous kidney disease
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
Bethesda, MarylandAges 18–90
Hear when a new Diabetic Nephropathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diabetic nephropathies?
- Yes. Clin2 currently lists 30 recruiting diabetic nephropathies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diabetic nephropathies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diabetic nephropathies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.